The genetic modification of ECN for IBD treatment involved introducing genes to enable the expression of interleukin-10 (IL-10), the ketone body (R)-3-hydroxybutyrate (3HB), and the immunomodulatory protein Sj16 from Schistosoma, along with other substances to treat intestinal-related inflammation [174]. Here, IL10 is linked to irritable bowel syndrome.